Advancing Novel Biotherapeutics Since 1995®

Investor Relations

Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory indications. We utilize our proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Click here to learn more.

More »Stock Quote

DYAX (Common Stock)
Exchange NASDAQ (US Dollars)
Price $6.73
Change (%) 0.07 (-1.03)%
Volume 937,300
Data as of Apr 17, 2014 4:00 PM ET
Delayed at least 20 minutes. Provided by eSignal.
Refresh Quote

More »Recent Releases

Date Title
Apr 17, 2014 Dyax Corp. to Host First Quarter 2014 Earnings Call and Webcast
Apr 16, 2014 Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Apr 3, 2014 Dyax Receives FDA Approval to Expand Use of KALBITOR® (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema to Patients 12 Years of Age and Older
Apr 2, 2014 Dyax Corp. to Participate in the 13th Annual Needham Healthcare Conference

More »Calendar of Events

Apr 30, 2014 Dyax Corp. 1Q 2014 Earnings Call

More » Event Archives

Apr 8, 2014 13th Annual Needham Healthcare Conference
Mar 3, 2014 2014 Cowen and Company 34th Annual Health Care Conference
Feb 28, 2014 Dyax Corp. 4Q 2013 Earnings Call
Feb 25, 2014 DX-2930 Phase 1a Data Review Webcast

Featured Financial Reports

Filing Date Title Type Size
Mar 3, 2014 10-K View HTML View PDF 878.8 KB Add to Briefcase
Dec 31, 2013 2013 Annual Report PDF  508.9 KB Add to Briefcase
Add to Briefcase = add file to Briefcase

You are now leaving Dyax.com.

The web site you are about to visit is . It is neither owned nor controlled by Dyax Corp. Dyax is not responsible for the content, products or services on this site.

Do you wish to continue?